Company intelligence / Profile preview
Noven Pharmaceuticals
Miami, Florida, United Statesnoven.com ↗
- Ownership
- Private
- Employees
- ~300
- Development stage
- Commercial
01
Overview
Noven has received FDA approval for nine products to date. Its commercialized products include the first and only transdermal patches approved for ADHD in children/adolescents and schizophrenia in adults. The company continues to develop new prescription transdermal systems with two developmental products pending regulatory review as of 2024.
- Therapeutic areas
- PsychiatryWomen's Health
- Modalities
- Transdermal drug delivery systems (patches)small molecule drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Rhone-Poulenc RorerCiba-GeigyHisamitsu (current collaboration on new technologies/products)
Beyond the preview
Go deeper on Noven Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noven Pharmaceuticals.